国家药监局发布系列APP 移动互联网助力药品监管

2019-08-04 佚名 国家药品监督管理局

为加快推进药品监管方式创新,推进应用互联网、大数据等新技术提升监管效能,国家药监局日前推出了系列移动应用APP,用便民、智能的方式提供权威、专业药品信息搜索,让消费者放心吃、安心查。先后发布的“食药云搜”、“E药云搜”是专注于药品、医疗器械、化妆品等领域,面向公众、行业、监管提供专业权威信息的移动应用产品。普通消费者、行业从业者、监管人员可采用方便快捷的一站式查询方式,实现“两品一械”等监管数据和

为加快推进药品监管方式创新,推进应用互联网、大数据等新技术提升监管效能,国家药监局日前推出了系列移动应用APP,用便民、智能的方式提供权威、专业药品信息搜索,让消费者放心吃、安心查。

先后发布的“食药云搜”、“E药云搜”是专注于药品、医疗器械、化妆品等领域,面向公众、行业、监管提供专业权威信息的移动应用产品。普通消费者、行业从业者、监管人员可采用方便快捷的一站式查询方式,实现“两品一械”等监管数据和相关新闻、监管动态、辟谣、曝光等公开信息的综合查询及关联展示。

系列移动应用APP的推出,建立了监管与公众、企业之间新的沟通渠道。“两品一械”等基础数据、监管动态等信息可以通过移动应用快速到达公众视线内,而公众通过移动应用也可以便捷地反馈“两品一械”相关违法违规信息。系列移动应用APP,通过移动互联技术提升政务服务水平,是监管者的“千里眼”,是公众的“顺风耳”,真正实现公众想什么、企业做什么、监管管什么三者联动,把更多用药安全信息送到群众手边,助力实现智慧监管。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1672246, encodeId=306e16e2246c0, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Sat Jul 18 12:10:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274273, encodeId=1e8712e42738d, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301691, encodeId=7c7e1301691d3, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371650, encodeId=fdbb13e16509f, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429232, encodeId=b24d1429232b9, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1672246, encodeId=306e16e2246c0, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Sat Jul 18 12:10:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274273, encodeId=1e8712e42738d, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301691, encodeId=7c7e1301691d3, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371650, encodeId=fdbb13e16509f, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429232, encodeId=b24d1429232b9, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1672246, encodeId=306e16e2246c0, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Sat Jul 18 12:10:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274273, encodeId=1e8712e42738d, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301691, encodeId=7c7e1301691d3, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371650, encodeId=fdbb13e16509f, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429232, encodeId=b24d1429232b9, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
    2019-08-06 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1672246, encodeId=306e16e2246c0, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Sat Jul 18 12:10:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274273, encodeId=1e8712e42738d, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301691, encodeId=7c7e1301691d3, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371650, encodeId=fdbb13e16509f, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429232, encodeId=b24d1429232b9, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]
    2019-08-06 wwzzly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1672246, encodeId=306e16e2246c0, content=<a href='/topic/show?id=84848e4625a' target=_blank style='color:#2F92EE;'>#药品监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87462, encryptionId=84848e4625a, topicName=药品监管)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b3026899023, createdName=yzh408, createdTime=Sat Jul 18 12:10:00 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1274273, encodeId=1e8712e42738d, content=<a href='/topic/show?id=04fd241222d' target=_blank style='color:#2F92EE;'>#互联网#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24122, encryptionId=04fd241222d, topicName=互联网)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2726119, createdName=july_975, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301691, encodeId=7c7e1301691d3, content=<a href='/topic/show?id=2ba78e935dc' target=_blank style='color:#2F92EE;'>#药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87935, encryptionId=2ba78e935dc, topicName=药监局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f5b299, createdName=xuyu, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1371650, encodeId=fdbb13e16509f, content=<a href='/topic/show?id=bf1ce2339d0' target=_blank style='color:#2F92EE;'>#监管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72339, encryptionId=bf1ce2339d0, topicName=监管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429232, encodeId=b24d1429232b9, content=<a href='/topic/show?id=321a409e058' target=_blank style='color:#2F92EE;'>#国家药监局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40970, encryptionId=321a409e058, topicName=国家药监局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b1e4178198, createdName=pyaili, createdTime=Tue Aug 06 02:10:00 CST 2019, time=2019-08-06, status=1, ipAttribution=)]

相关资讯

药监局宣布批准带状疱疹疫苗和骨瘤新药

国家药品监督管理局(NMPA)宣布,批准了两款新药在中国上市。

国家药监局:正在积极建设疫苗追溯的协同平台、监管平台

6月29日,十三届全国人大常委会第十一次会议举行了闭幕会,会议以170票赞成、1票弃权,表决通过了疫苗管理法。会后,全国人大常委会办公厅新闻发布会。国家药品监督管理局药品监管司司长袁林说,新颁布的疫苗管理法明确提出,要对疫苗实行全程的电子追溯制度,由国务院的药品监督管理部门会同国务院的卫生健康部门,制定统一的疫苗的追溯标准,还有相应的规范。建立全国疫苗信息化追溯的协同平台,整合疫苗生产、流通、预防

聚焦!国家药监局扩大医疗器械注册人制度试点啦!

为了给全面实施医疗器械注册人制度进一步积累经验,国家药品监督管理局决定在上海、广东、天津自贸区开展医疗器械注册人制度试点工作的基础上,进一步扩大医疗器械注册人制度试点工作,试点范围包括北京、天津、河北、辽宁、黑龙江、重庆等地。并于即日发布通知。全文如下:国家药监局关于扩大医疗器械注册人制度试点工作的通知北京、天津、河北、辽宁、黑龙江、上海、江苏、浙江、安徽、福建、山东、河南、湖北、湖南、广东、

药监局重磅发布:2018年度药品审评报告

7月1日,国家药品监督管理局药品审评中心官网发布了2018年度药品审评报告。2018年,国家药品监督管理局药品审评中心(以下简称药审中心)在国家药品监督管理局(以下简称国家局)坚强领导下,继续贯彻落实中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》(厅字〔2017〕42号,以下简称42号文件)和国务院《关于改革药品医疗器械审评审批制度的意见》(国发〔2015〕44

首部疫苗管理法来了!实行严格管理制度,12月1日起施行

《中华人民共和国疫苗管理法》自2019年12月1日起施行。这是我国对疫苗管理进行的专门立法,对疫苗违法犯罪行为规定了严厉处罚,明确疫苗犯罪行为依法从重追究刑事责任等。

国家药监局:药品上市许可持有人数据库上线,公众可官网检索

8月2日,国家药品监督管理局发布消息,药品上市许可持有人数据库(以下简称:持有人数据库)上线。截至2019年7月底,该数据库共纳入上市许可持有人品种3239个(以药品批准文号计),上市许可持有人主体156个。国家药监局称,有关业务司局、直属单位、省级监管部门可通过数据共享平台查询药品上市持有人相关数据。在新的持有人数据库中增加依权限的数据下载功能,为监管部门提供全面的数据服务,系统内用户可登录国家